Drug Safety

Labelling and ‘Dear Doctor’ Letters: Are They Noncommittal?
pp. 1051-1055(5)
Authors: van Grootheest A.C.K.; Edwards I.R.

Minimising the Long-Term Adverse Effects of Childhood Leukaemia Therapy
pp. 1057-1077(21)
Authors: Langebrake C.; Reinhardt D.; Ritter J.

Comparative Tolerability of Contrast Media Used for Coronary Interventions
pp. 1079-1098(20)
Authors: Esplugas E.; Cequier A.; Gomez-Hospital J.A.; Del Blanco B.G.; Jara F.

Monitoring and Assessing the Safety of Disease-Modifying Antirheumatic Drugs: A West Midlands Experience
pp. 1099-1105(7)
Authors: Jobanputra P.; Maggs F.; Homer D.; Bevan J.

Glucose Intolerance with Atypical Antipsychotics
pp. 1107-1116(10)
Authors: Hedenmalm K.; Hägg S.; Ståhl M.; Mortimer Ö.; Spigset O.